CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 295 enrolled
Drug / intervention
Mometasone 220mcg BID +2 moredrug
Likely dose
Mometasone 220mcg BIDfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02066298
NCT02066298Phase 3Completed
CompareCT.gov

Steroids In Eosinophil Negative Asthma

Milton S. Hershey Medical Center·interventional·Posted Feb 19, 2014·Updated May 29, 2019

In Brief

A Phase 3 clinical trial evaluating Mometasone 220mcg BID, Tiotropium Respimat 5mcg QD, and 1 other intervention for Asthma. Completed, enrolled 295 participants across 25 sites.

Detailed Summary

Because approximately half of all mild-moderately-severe asthma is persistently non-eosinophilic, it is important to determine prospectively if patients who are persistently non-eosinophilic differ in their benefit from inhaled corticosteroid treatment compared to patients who are not persistently non-eosinophilic.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 19, 2014
Enrollment StartJul 1, 2014
Primary CompletionMay 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 12.4 years ago

Interventions

Mometasone 220mcg BIDdrug

Mometasone is an ICS

Tiotropium Respimat 5mcg QDdrug

Tiotropium is a LMA

Placebodrug